This product was successfully added to cart!
4-Chloro-5-sulfamoylanthranilic Acid
品牌商品推荐
更多 >>-
3-甲硫基-1,2,4-三嗪
-
4-(2,3-二氯苯基)-1,4-二氢-2,6-二甲基-3,5-吡啶二甲酸甲基(1-丁酰氧基)甲酯
-
4-氟苯基溴化镁
-
Caesalmin B
-
1H-咪唑并[4,5-d]哒嗪-2-胺
-
6-氧代螺[3.3]庚烷-2-羧酸甲酯
商品详情
客户评价
| 密度 | 1.726g/cm3 |
|---|---|
| 沸点 | 549.2?C at 760mmHg |
| 分子式 | C7H7ClN2O4S |
| 分子量 | 250.65900 |
| 闪点 | 286?C |
| 精确质量 | 249.98200 |
| PSA | 131.86000 |
| LogP | 2.63010 |
| 折射率 | 1.665 |
| 符号 |
GHS07 |
|---|---|
| 信号词 |
Warning |
| 危害声明 |
H315-H319-H335 |
| 警示性声明 |
P305 + P351 + P338 |
| 危险品运输编码 | NONH for all modes of transport |
| 海关编码 | 2935009090 |
|
~51%
4-Chloro-5-sulf…
3086-91-7
|
|
文献：NITROMED, INC. Patent: WO2006/55542 A2, 2006 ; Location in patent: Page/Page column 69-70 ; WO 2006/055542 A2 |
|
~%
4-Chloro-5-sulf…
3086-91-7
|
|
文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ; |
|
~%
4-Chloro-5-sulf…
3086-91-7
|
|
文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ; |
|
~%
4-Chloro-5-sulf…
3086-91-7
|
|
文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 |
|
~29%
4-Chloro-5-sulf…
3086-91-7
|
|
文献：Tetrahedron, , vol. 67, # 49 p. 9518 – 9521 |
![4-chloro-2-[(2,5-dimethoxy-2,5-dihydro-furan-2-ylmethyl)-amino]-5-sulfamoyl-benzoic acid结构式](https://www.chemsrc.com/caspic/316/1351169-05-5.png)
| 4-Chloro-5-sulfamoylanthranilic Acid上游产品? 5 | |
|---|---|
|
|
|
|
|
| 4-Chloro-5-sulfamoylanthranilic Acid下游产品? 1 | |
|
|
|
| 海关编码 | 2935009090 |
|---|---|
| 中文概述 | 2935009090 其他磺（酰）胺. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:35.0% |
| 申报要素 | 品名, 成分含量, 用途 |
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
|
The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol. Toxicol. (Copenh.) 49(3) , 223-9, (1981)
Three principles for the use of HPLC with spectrophotometric detection to determine the concentration of furosemide and of 4-chloro-5-sulfamoyl anthranilic acid (CSA) were studied. A reversed phase mi…
|
|
|
The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon. Acta Pharmacol. Toxicol. (Copenh.) 47(3) , 202-7, (1980)
The percentual binding of furosemide (5 micrograms/ml) was slightly but significantly lower in serum from elderly patients than in serum from normal blood donors (96.5 +/- 0.7 versus 97.9 +/- 0.3). A …
|
|
|
Furosemide accelerates gentamicin accumulation in cultured renal cells (LLC-PK1 cells). Nephron 53(2) , 138-41, (1989)
Furosemide is known to potentiate gentamicin nephrotoxicity. The mechanism of potentiation is unclear. In our previous studies, we demonstrated that furosemide enhanced gentamicin accumulation in rabb…
|
|
|
4-Chloro-5-sulfamoylanthranilic acid |
|
2-AMINO-5-AMINOSULFONYL-4-CHLOROBENZOIC ACID |
|
4-chloro-5-sulphamoyl anthranilic acid |
|
Desfurylmethylfurosemide |
|
Saluamine |
|
2-amino-4-chloro-5-sulfamoyl-benzoic acid |
|
Furosemide Related Compound B |
|
EINECS 221-408-7 |
|
4-chloro-5-sulfamoyl-anthranilic acid |
|
4-Chloro-5-sulfanilanthranilic acid |
-
海量货源
1000+化工产品，覆盖300+小类
-
精品服务
我们以卓越的服务 已经有超过100家合作伙伴
-
使命
科技成就美好出行
-
核心价值观
成就客户、价值为纲、开放诚信 以奋斗者为本